Regeneron Officer Joseph LaRosa Files Form 144 to Sell $4.31M in Common Stock

Executive Summary

On November 2, 2026, Joseph LaRosa, an Officer of Regeneron Pharmaceuticals, Inc., filed a Form 144 notice disclosing the proposed sale of 4,466 shares of common stock through UBS Financial Services Inc. The aggregate market value of the proposed transaction is approximately $4.31 million, based on an estimated price of $965.49 per share.

Transaction Details

• Security: Common Stock
• Shares to be Sold: 4,466
• Aggregate Market Value: $4,311,875.12
• Approximate Sale Date: November 2, 2026
• Shares Outstanding: 101,630,713
• Origin of Shares: Acquired on January 3, 2024, via stock option exercise directly from the issuer.
• Past 3-Month Activity: The filer indicated 'Nothing to Report' regarding prior securities sold in the preceding three months.

Market Impact & Significance

While the total dollar value ($4.31 million) is substantial, the volume represents less than 0.005% of Regeneron's 101.63 million outstanding common shares. As the shares stem from an option exercise and represent standard executive compensation realization, the transaction carries medium significance with negligible dilution or direct market pressure.